Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

American Journal of Psychiatry

Volumn 154, Issue 9, 1997, Pages 1248-1254

  Tollefson, Gary D ^a   Beasley Jr , Charles M ^a   Tamura, Roy N ^a   Tran, Pierre V ^a   Potvin, Janet H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; TARDIVE DYSKINESIA;

EID: 0030880365     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.9.1248     Document Type: Article

References (42)

1. Deniker P: Introduction of neuroleptic chemotherapy into psychiatry, in Discoveries in Biological Psychiatry. Edited by Ayd FJ, Blackwell B. New York, Wiley-Interscience, 1970, pp 155-164
2. Casey DE, Keepers GA: Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia, in Psychopharmacology: Current Trends. Edited by Casey DE, Christensen AV. Berlin, Springer-Verlag, 1988, pp 74-93
3. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M: Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacol Bull 1984; 20:39-40
4. Smith JM, Baldessarini RJ: Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37:1368-1373
5. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J: Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22:254-258
6. Casey D: Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia, in Schizophrenia. Edited by Hirsch SR, Weinberger DR. London, Blackwell Science, 1995, pp 546-565
7. Bymaster FP, Calligaro DO, Falcone JF, Marsh AD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
8. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC: The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 1993; 2:281-293
9. Stockton ME, Rasmussen K: Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology (Berl) 1996; 124: 50-56
10. Stockton ME, Rasmussen K: Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14:97-104
11. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus haloperidol: acute phase results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacology 1996; 14:111-123
12. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN: Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7:125-137
13. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
14. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
15. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 1982; 39:486-487
16. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
17. Kay SR, Opler LA, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health Systems, 1986
18. SAS/STAT User's Guide, version 6, 4th ed, vols 1, 2. Cary, NC, SAS Institute, 1990
19. Berry DA: Logarithmic transformations in ANOVA. Biometrics 1987; 43:439-456
20. Casey DE, Gerlach J: Tardive dyskinesia: what is the long-term outcome? in Tardive Dyskinesia and Neuroleptics: From Dogma to Reason. Edited by Casey DE, Gardos G. Washington, DC, American Psychiatric Press, 1986, pp 76-97
21. Barnes TRE, Kidger T, Gore SM: Tardive dyskinesia: a 3-year follow-up study. Psychol Med 1983; 13:71-81
22. Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8:52S-56S
23. Glazer WM, Morgenstern H, Doucette JT: Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993; 54:133-139
24. Casey DE: Spontaneous and tardive dyskinesia: clinical and laboratory studies. J Clin Psychiatry 1985; 46:42-47
25. Lieberman J, Kane J, Woerner M: Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 20:22-26
26. Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA: Incidence and correlates of tardive dyskinesia in first episode schizophrenia. Arch Gen Psychiatry 1996; 53:313-319
27. Casey DE: Tardive dyskinesia, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987, pp 1411-1419
28. Andersson U, Eckernas SA, Hartvig P, Ulin J, Langstrom B, Haggstrom JE: Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J Neural Transm 1990; 79:215-226
29. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR: D1 and D2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250:1429-1432
30. Moore NA, Tye NC, Axton MS, Risius FC: The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992; 262:545-551
31. Skarsfeldt T: Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995; 281:289-294
32. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW: Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996; 124:87-94
33. Gao X-M, Sakai K, Tamminga CA: Chronic olanzapine or sertindole treatment results in reduced oral dyskinesias in rats compared to haloperidol. Biol Psychiatry (in press)
34. Pilowsky LS, Basatto GF, Taylor M, Costa DC, Sharma T, Sigmundson T, Ell PJ, Nohria V, Kerwin RW: Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 1231 IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996; 124:148-153
35. Beasley CM Jr, Sanger TM, Satterlee WG, Tollefson GD, Tran PV, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124:159-167
36. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
37. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
38. Chouinard G, Annable L, Mercier P, Ross-Chouinard A: A five-year follow-up study of tardive dyskinesia. Psychopharmacol Bull 1986; 22:259-263
39. Rivest R, Marsden CA: Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not haloperidol. Br J Pharmacol 1991; 104:234-238
40. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW: Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995; 120:67-74
41. Sweet RA, Mulsant BH, Gupta R, Rifai AH, Pasternak RE, McEachran A, Zubenko GS: Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995; 52:478-486
42. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 66: 2402-2406